A Study of MRG003 in Patients With Advanced Solid Tumors

Inclusion Criteria:

* Willing to sign the ICF and follow the requirements specified in the protocol.
* Age: ≥18 years and ≤75 years, both genders
* Expected survival time≥12 weeks
* Phase Ia: Patients with histologically and cytologically confirmed advanced or metastatic solid tumor
* Phase Ib: Patients with histologically and cytologically confirmed EGFR-positive advanced or metastatic colorectal cancer, squamous cell carcinoma of head and neck, and nasopharyngeal carcinoma
* Subjects must have measurable lesions according to the response Evaluation Criteria In Solid Tumors（RECIST v1.1）
* ECOG performance score 0 or 1
* Acceptable liver, renal, and hematologic function
* Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment

Exclusion Criteria:

* History of hypersensitivity to any component of the investigational product
* Presence of central nervous system metastasis
* Prior history of other primary malignancies
* Known history of clinically significant hepatic diseases
* Evidence of active infection of human immunodeficiency virus (HIV)
* History of ophthalmic abnormalities
* Any severe or uncontrolled systemic disease judged by the investigator
* Patients with poorly controlled heart diseases
* Received radiotherapy, chemotherapy, biotherapy, immunotherapy or other anti-tumor drugs within 4 weeks prior to the first dose of study treatment
* Major surgery or surgical therapy for any cause within 4 weeks prior to the first dose of investigational drug
* Planned surgery or surgery is the best interest of patients as determined by investigator
* History of severe skin disease requiring interruption of previous EGFR targeted therapy; or chronic skin disease requiring oral or intravenous therapy
* Active concomitant diseases that might increase risks of toxicity
* Pregnancy, or breast feeding